Straits Times Index
3,297.00 -17.05 (-0.51%) Nikkei
38,946.93 -122.75 (-0.31%) Hang Seng
19,219.80 -416.42 (-2.12%) FTSE 100
8,388.66 -35.54 (-0.42%) Bitcoin USD
71,012.52 +4,348.13 (+6.52%) CMC Crypto 200
1,529.54 +41.00 (+2.75%)
AZN Jan 2026 47.500 call
| Previous close | 24.50 |
| Open | 24.50 |
| Bid | 30.55 |
| Ask | 35.20 |
| Strike | 47.50 |
| Expiry date | 2026-01-16 |
| Day's range | 24.50 - 24.50 |
| Contract range | N/A |
| Volume | |
| Open interest | 20 |
ReutersAstraZeneca aims for $80 billion in total revenue by 2030
AstraZeneca, which laid out targets as part of its investor day event, reported total revenue of $45.81 billion last year. CEO Pascal Soriot has rebuilt the company's pipeline of new drugs since taking the helm more than a decade ago, with blockbusters such as lung cancer drug Tagrisso, leukaemia drug Calquence and Farxiga for diabetes. AstraZeneca, which is facing patent expiries on some key drugs, said it would continue to invest in new technologies and platforms that will "shape the future of medicine" beyond 2030.
Business WireAstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030
CAMBRIDGE, England, May 21, 2024--Investor Day 2024
BenzingaAmgen/AstraZeneca Say Asthma Drug Shows Activity In Another Lung Disease Across Broad Patient Population
Sunday, Amgen Inc (NASDAQ:AMGN) and AstraZeneca Plc (NASDAQ:AZN) announced the results of the Phase 2a COURSE trial of Tezspire (tezepelumab-ekko) for severe chronic obstructive pulmonary disease (COPD) with a broad range of baseline blood eosinophil counts (BEC) irrespective of emphysema, chronic bronchitis or smoking status. The primary results showed that treatment with Tezspire led to a 17% numerical reduction in the annual rate of moderate or severe COPD exacerbations compared to placebo at
